S&P 500   3,954.80 (-0.22%)
DOW   33,681.58 (-0.30%)
QQQ   283.60 (-0.09%)
AAPL   142.28 (-0.26%)
MSFT   245.77 (-0.66%)
META   115.50 (+0.15%)
GOOGL   93.89 (+0.19%)
AMZN   89.65 (-0.77%)
TSLA   178.11 (+2.69%)
NVDA   173.55 (+1.08%)
NIO   13.00 (-3.06%)
BABA   93.06 (-1.18%)
AMD   69.39 (-1.53%)
T   19.25 (+0.68%)
MU   55.47 (+0.49%)
CGC   3.00 (-2.91%)
F   13.28 (+1.22%)
GE   82.54 (-1.30%)
DIS   93.55 (+1.08%)
AMC   6.02 (-0.82%)
PYPL   74.21 (-0.01%)
PFE   51.97 (+0.37%)
NFLX   323.95 (+4.41%)
S&P 500   3,954.80 (-0.22%)
DOW   33,681.58 (-0.30%)
QQQ   283.60 (-0.09%)
AAPL   142.28 (-0.26%)
MSFT   245.77 (-0.66%)
META   115.50 (+0.15%)
GOOGL   93.89 (+0.19%)
AMZN   89.65 (-0.77%)
TSLA   178.11 (+2.69%)
NVDA   173.55 (+1.08%)
NIO   13.00 (-3.06%)
BABA   93.06 (-1.18%)
AMD   69.39 (-1.53%)
T   19.25 (+0.68%)
MU   55.47 (+0.49%)
CGC   3.00 (-2.91%)
F   13.28 (+1.22%)
GE   82.54 (-1.30%)
DIS   93.55 (+1.08%)
AMC   6.02 (-0.82%)
PYPL   74.21 (-0.01%)
PFE   51.97 (+0.37%)
NFLX   323.95 (+4.41%)
S&P 500   3,954.80 (-0.22%)
DOW   33,681.58 (-0.30%)
QQQ   283.60 (-0.09%)
AAPL   142.28 (-0.26%)
MSFT   245.77 (-0.66%)
META   115.50 (+0.15%)
GOOGL   93.89 (+0.19%)
AMZN   89.65 (-0.77%)
TSLA   178.11 (+2.69%)
NVDA   173.55 (+1.08%)
NIO   13.00 (-3.06%)
BABA   93.06 (-1.18%)
AMD   69.39 (-1.53%)
T   19.25 (+0.68%)
MU   55.47 (+0.49%)
CGC   3.00 (-2.91%)
F   13.28 (+1.22%)
GE   82.54 (-1.30%)
DIS   93.55 (+1.08%)
AMC   6.02 (-0.82%)
PYPL   74.21 (-0.01%)
PFE   51.97 (+0.37%)
NFLX   323.95 (+4.41%)
S&P 500   3,954.80 (-0.22%)
DOW   33,681.58 (-0.30%)
QQQ   283.60 (-0.09%)
AAPL   142.28 (-0.26%)
MSFT   245.77 (-0.66%)
META   115.50 (+0.15%)
GOOGL   93.89 (+0.19%)
AMZN   89.65 (-0.77%)
TSLA   178.11 (+2.69%)
NVDA   173.55 (+1.08%)
NIO   13.00 (-3.06%)
BABA   93.06 (-1.18%)
AMD   69.39 (-1.53%)
T   19.25 (+0.68%)
MU   55.47 (+0.49%)
CGC   3.00 (-2.91%)
F   13.28 (+1.22%)
GE   82.54 (-1.30%)
DIS   93.55 (+1.08%)
AMC   6.02 (-0.82%)
PYPL   74.21 (-0.01%)
PFE   51.97 (+0.37%)
NFLX   323.95 (+4.41%)
NASDAQ:ADVM

Adverum Biotechnologies ESG Rating & Sustainability Data

$0.62
-0.01 (-1.59%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.62
$0.65
50-Day Range
$0.62
$1.03
52-Week Range
$0.62
$2.04
Volume
531,260 shs
Average Volume
661,915 shs
Market Capitalization
$61.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Key ESG Takeaways for Adverum Biotechnologies

The keytakeaways are AI-generated and highlight the main contributors behind the net impact scores of Adverum Biotechnologies. The insights are based on millions of scientific articles, along with the company-specific product and service portfolio.
  • Adverum Biotechnologies seems to create the most significant positive value in categories , , and . The largest positive contribution comes from its impact, which is false driven by its Clinical research services for physiological diseases , Preclinical research services for mental health, and Preclinical research services for physical health products.
  • On the other hand, these positive outcomes are achieved by using resources or causing negative impacts in categories , , and . The negative contribution in the impact category is driven by its Clinical research services for physiological diseases , Preclinical research services for mental health, and Preclinical research services for physical health products.
  • To improve its net impact, a company can either grow its positive impacts, or reduce its negative impacts. For example, by doubling its Preclinical research services for physical health business, Adverum Biotechnologies would improve its net impact ratio by 1 percentage points.

ADVM Impact Ratio

Net impact ratio represents the net impact of a company. It is defined as the (positive impacts - negative impacts) / positive impacts. The maximum value for net impact ratio is 100%, representing a theoretical company with no negative impacts. The minimum value is -∞. Net scores depend on the value sets that determine the importance of different impact categories.
+77.3%
The default value set, where each category is given the same weight.

Value Sets Value sets can be used to assess how different stakeholder values or emphasis on certain values might affect the net impact ratio.

Millennials
Value set of millennials (b. 1980 - 1999), based on Upright's annual Impact at Work survey.
+80.9%
Most Wanted Workforce
Value set of the most wanted workforce, based on Upright's annual Impact at Work survey.
+74.7%
Society First
Value set that emphasizes society impacts over other impacts.
+62.8%
Knowledge First
Value set that emphasizes knowledge impacts over other impacts.
+91.5%
Health First
Value set that emphasizes health impacts over other impacts.
+83.7%

Adverum Biotechnologies ESG Score + Net Impact Profile

ImpactNegativeScorePositive
+3.61
+3.61
+1.88
+1.88
+0.00
+0.00
-0.01
+0.02
+0.03
-0.09
+0.02
+0.11
0.00
+0.00
+6.25
+6.25
-0.00
0.00
+0.00
-2.38
-2.38
-0.45
+3.34
+3.80
-0.03
+0.58
+0.61
0.00
+0.00
-0.00
0.00
+0.00
-0.00
+0.17
+0.17
-0.23
-0.23
+0.00
-0.06
-0.06
+0.00
-0.05
-0.05
+0.00
-0.07
-0.07
+0.00
-0.37
-0.37
+0.00

Upright Model Version 0.4.0
ESG Data Last Updated: April 1, 2022


About Upright's Net Impact Model

Upright's Net Impact Data quantifies the holistic value creation and impact of companies. It details both the negative and positive impacts a company has on the environment, health of people, society and knowledge, and forms a net sum of these costs and gains based on the economic costs of each impact category. The data is produced by Upright's Net Impact model, which is a mathematical model of the economy that produces continuously updated estimates of the net impact of companies by means of an information integration algorithm. The data is primarily sourced from the CORE open access database, which contains over 200 million scientific papers. Other sources of data include open databases published by the World Bank, IMF, WHO, OECD, IPCC, CDC and USDA.













Adverum Biotechnologies ESG Rating - Frequently Asked Questions

How is Adverum Biotechnologies doing in terms of sustainability?

According to The Upright Project, which measures holistic value creation and impact of companies, Adverum Biotechnologies has a net impact ratio of 77.3%, indicating an overall positive sustainability impact. Adverum Biotechnologies seems to create the most significant positive value in the categories of Creating knowledge, Physical diseases, and Jobs. On the other hand, these positive outcomes are achieved by using resources or causing negative impacts in the categories of Scarce human capital, Physical diseases, and Waste. Learn more on the sustainability of Adverum Biotechnologies.

This page (NASDAQ:ADVM) was last updated on 12/9/2022 by MarketBeat.com Staff